Oxford BioDynamics Plc (AIM:OBD)

Market Cap	8.15M +11.1%
Revenue (ttm)	1.10M +72.2%
Net Income	-11.15M
EPS	-0.01
Shares Out	4.29B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,809,605
Open	0.1960
Previous Close	0.1900
Day's Range	0.1785 - 0.2000
52-Week Range	0.1685 - 0.7800
Beta	-0.19
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 5, 2026

About Oxford BioDynamics

Oxford BioDynamics Plc, together with its subsidiaries, operates as a biotechnology company that y developing, and commercializing precision medicine tests for life-changing diseases in the United States and the United Kingdom. The company provides EpiSwitch CiRT (Checkpoint inhibitor Response Test), a blood test that predicts an individual patient's therapeutic response to checkpoint inhibitor immunotherapy. EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarker. Its p...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 41
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: OBD

Financial Performance

In fiscal year 2025, Oxford BioDynamics's revenue was 1.10 million, an increase of 72.17% compared to the previous year's 636,000. Losses were -11.15 million, -3.58% less than in 2024.